We’ve had a longstanding interest in a topic, cross-jurisdictional class action tolling, the very name of which screams “esoteric”. You might think that it screams something worse than that, but hey, we’re guys who blog about drug and medical device litigation for fun – so we’re incapable of being insulted in that fashion.
Anyway, because
The response to our post in January on the Blain class action denial in the Paxil litigation, as well as the likely fallout from the just-decided reversal of class certification in Regents of University of California v. Credit Suisse First Boston (USA), Inc., 2007 WL 816518 (5th Cir. Mar. 19, 2007) (the subject of
Bexis got an unexpected present for his 51st birthday yesterday. The court denied certification of a nationwide suicidality class in the latest Paxil litigation. See Blain v. Smithkline Beecham Corp., 2007 WL 178564 (E.D. Pa. Jan. 25, 2007). This got us thinking more about what’s really going on with pharmaceutical class actions. We can’t